Prolonged oral etoposide for advanced uterine leiomyosarcoma with pulmonary metastases: Case report

European Journal of Gynaecological Oncology

Volumn 18, Issue 2, 1997, Pages 97-100

  Termrungruanglert, W ^a   Kudelka, A P ^b,d   Piamsomboon, S ^c   Edwards, C L ^b   Tornos, C ^b   Kavanagh, J J ^b  

^a KING CHULALONGKORN MEMORIAL HOSPITAL   (Thailand)

^b UNIVERSITY OF TEXAS   (United States)

^c MAHIDOL UNIVERSITY   (Thailand)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Leiomyosarcoma; Oral etoposide; Uterus

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; ETOPOSIDE; PACLITAXEL;

ADULT; ARTICLE; CASE REPORT; DRUG EFFICACY; FEMALE; FOLLOW UP; HUMAN; LEIOMYOSARCOMA; LONG TERM CARE; LUNG METASTASIS; NEUTROPENIA; ORAL DRUG ADMINISTRATION; PARAAORTIC LYMPH NODE; PERIPHERAL NEUROPATHY; RADICAL HYSTERECTOMY; SALPINGOOOPHORECTOMY;

ADMINISTRATION, ORAL; ANTINEOPLASTIC AGENTS, PHYTOGENIC; COMBINED MODALITY THERAPY; DRUG ADMINISTRATION SCHEDULE; ETOPOSIDE; FEMALE; HUMANS; LEIOMYOSARCOMA; LUNG NEOPLASMS; MIDDLE AGED; UTERINE NEOPLASMS;

EID: 0030897246     PISSN: 03922936     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Aaro L. A., Symmonds R. E., Dockery M. B.: "Sarcoma of the uterus: a clinical and pathological study of 177 cases". Am. J. Obstet. Gynecol., 1996, 94, 101.
2. Silverberg S. G.: "Leiomyosarcoma of the uterus: a clinicopathologic study". Obstet. Gynecol., 1971, 38, 613.
3. Hart R W., Billman J. K.: "A reassessment of uterine neoplasms originally diagnosed as leiomyosarcoma". Cancer, 1978, 41, 1902.
4. Vardi J. R., Tovell H. M.: "Leiomyosarcoma of the uterus: clinico-pathologic study". Obstet. Gynecol., 1980, 56, 428.
5. Hannigan E. V., Gomez L. G.: "Uterine leiomyosarcoma: a review of prognostic and pathologic features". Am. J. Obstet. Gynecol., 1979, 134, 557.
6. Kempson R. L., Bari W.: "Uterine sarcomas: classification. diagnosis and prognosis". Hum. Pathol., 1970, 14, 331.
7. Gadducci A., Fabrini M. G., Bonuccelli A., Moda S., Fanucchi A., Laddaga M., Facchini V.: "Analysis of treatment failures in patients with early-stage uterine leiomyosarcoma". Anticancer Research., 1995, 15, 485.
8. Salazar O. M , Bonfiglio T. A., Patten S. F. et al.: "Uterine sarcomas. Natural history, treatment, and prognosis". Cancer, 1978, 42, 1152.
9. Barter J. F., Smith E. B., Szpak C. A. et al.: "Leiomyosarcoma of the uterus: clinicopathologic study of 21 cases". Gynecol. Oncol., 1985, 21, 220
10. Kahanpaa K V., Wahlstrom T., Grohn P. et al.: "Sarcoma of the uterus: a clinicopathologic study of 119 patients". Obstet Gynecol., 1986, 67, 457.
11. Berchuck A., Rubin S. C., Hoskins W. J., Saigo P. E., Pierce V. K., Lewis J. L. jr.: "Treatment of uterine leiomyosarcoma". Obstet. Gynecol., 1988, 71, 845.
12. Antman K. H.: "Uterine sarcoma". In: Knapp R. C., Berkowitz R. S. eds.: "Gynecologic Oncology", First edition. New York, Macmillan, 1986, 297.
13. Hawkins R. E., Wiltshaw C., Nasi J. L.: "Ifosfamide with and without adriamycin in advanced uterine leiomyosarcoma". Cancer Chemoter. Pharmacol., 1990, 26 (Suppl ), 26.
14. Omura G. A., Major F. J., Blessing J. A., Sedlacek T. V., Thigpen J. T , Creasman W. T., Zaino R. J.: "A randomization study of adriamycin with and without dimethyltriazenoimidazole-carboxamide in advanced uterine sarcoma". Cancer, 1983, 52, 626.
15. Hannigan E V., Freedman R. S., Elder R. W. et al.: "Treatment of advanced uterine sarcomas with vincristine, actinomycin D, and cyclophosphamide". Gynecol. Oncol., 1983, 15, 224.
16. Thigpen J. T., Blessing J. A., Wilbanks G. D.: "Cisplatin as second line therapy in the treatment of advanced or recurrent leiomyosarcoma of the uterus: a phase II trial of the Gynecologic Oncology Group". Am. J. Clin. Oncol., 1986, 9, 18.
17. Sutton G. P., Blessing J. A., Barrett R. J., McGhee R.: "Phase II trial of ifosfamide and mesna in leiomyosarcoma of the uterus: a Gynecologic Oncology Group study". Am. J. Obstet. Gynecol., 1992, 166, 556.
18. Sutton G. P., Blessing J. A., Malfetano J. H.: "A phase II trial of doxorubicin, ifosfamide and mesna in patients with advanced or recurrent uterine leiomyosarcoma". Proc. Am. Soc. Clin. Oncol., 1993, 12, 217.
19. Soper J. T., Evans A. C., Rodriquez G. et al.: "Etoposideplatin combination therapy for chemorefractory gestational trophoblastic disease". Gynecol. Oncol., 1995, 56, 421.
20. Slevin M. L., Clark P. I , Joel S. P. et al.: "A randomized trial to evaluate the effect of schedule on the activity of etoposide in small cell lung cancer". J. Clin. Oncol., 1989, 7, 1333.
21. Hainsworth J. D., Johnson D. H., Frazier S. R., Greco F. A.: "Chronic daily administration of oral etoposide: a phase I trial". J. Clin. Oncol., 1989, 7, 396
22. Greco F. A.: "Chronic etoposide administration: overview of clinical experience". Cancer Treat. Rev., 1993, 19 (Suppl. C), 35.
23. Kavanagh J. J., Tresukosol D., Gonzalez de Leon C., Edwards C. L., Freedman R. S., Hord M., Howell E., Lenzi R., Krakoff I. H., Kudelka A. P.: "Phase II study of prolonged oral etoposide in refractory ovarian cancer". Intl. J. Gynecol. Cancer, 1995, 5, 351.
24. Garrow G. C., Hainsworth J. D., Johnson D. H.: "Prolonged administration of oral etoposide in previously treated epithelial ovarian cancer: a phase II trial". Proc. Am. Soc. Clin. Oncol., 1991, 11, 36.
25. Currie J. L., Blessing J. A., Muss H. B., Fowler J., Berman M., Burke T. W.: "Combination chemotherapy with hydroxyurea, dacarbazine (DTIC), and etoposide in the treatment of uterine leiomyosarcoma: a Gynecologic Oncology Group study". Gynecol. Oncol., 1996, 61, 27
26. Fukunishi H., Yukimura N., Tadeuchi S , Kitazawa S.: "Uterine myxoid leiomyosarcoma and CYVADIC-etoposide therapy: case report". Intl. J. Gynecol. Obstet., 1994, 46, 321.
27. Chantarawiroj P., Tresukosol D., Kudelka A. P., Edwards C. L., Silva E. G., Wharton J. T., Kavanagh J. J.: "Prolonged oral etoposide for refractory advanced uterine leiomyosarcoma: case report" Gynecol. Oncol., 1995, 58, 248
28. Berman E., Adams M., Durgou-Osterndorf R., Godfrey L., Clarkson B., Andreeff M.: "Effect of tamoxifen on cell lines displaying the multidrugresistant phenotype". Blood, 1991, 77, 818.
29. Smith D. C., Trump D. L.: "A phase I trial of high-dose oral tamoxifen and CHOPE (cyclophosphamide, doxorubicin. vincristine, prednisolone, etoposide)". Cancer Chemother. Pharmacol., 1995, 36, 65.
30. Millward M. J., Cantwell B. M. J., Lien E. A., Carmichael J., Harris A. L., "Intermittent high-dose tamoxifen as a potential modifier of multidrug resistance". Eur. J. Cancer, 1992, 28, 805.
31. Stuart N. S. A., Philip P , Harris A. L., Tonkin K., Houlbrook S., Kirk J., Lien E. A., Carmichael J.: "High dose tamoxifen as an enhancer of etoposide cytotoxicity. Clinical effects and in vitro assessment in p-glycoprotein expressing cell lines". Br. J. Cancer, 1992, 66, 833.
32. Millward M. J., Lien E. A., Robinson A., Cantwell B. M. J.: "High-dose (480 mg/day) tamoxifen with etoposide: a study of a potential multi-drug resistance modulator". Oncology, 1994, 51, 79.